Resources

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, explores Biosolutions, defining what they are and their potential to solve global challenges beyond health.

As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.

Coulter Partners successfully led a search assignment for Trevi Therapeutics, placing David Hastings as Chief Financial Officer (CFO).

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.

This week JPM kicks off in San Francisco with BIA hosting a UK Reception. A significant week for BIA too with the long-awaited announcement of our new CEO.

We are delighted to announce the appointment of Professor Chris Molloy as our new Chief Executive Officer, starting in May 2026.

Amici Procurement Solutions Rebrands as MyAmici. The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, end-to-end LabOps platform supporting biotech, medtech, and life-science organisations across every stage of growth.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.

NRG Therapeutics Ltd has announced that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.

Engitix announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt.

EnteroBiotix Limited announced positive final results from for EBX-102-02, a therapeutic for irritable bowel syndrome with constipation and diarrhoea.

Relation and healthcare investment firm Deerfield Management, a current investor,  has launched a new research collaboration to advance therapeutic discovery projects for diseases of high unmet need.

Coulter Partners completed a search assignment for Alethio Therapeutics, placing Dr. Rohit Batta as Chief Executive Officer.

Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.

Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.

Happy New Year to all our BIA members and collaborators. We hope that the break has provided an opportunity for a refresh, ready for a jam-packed 2026. Many of you will be heading to JPM – don't miss the UK reception.

Working closely with BIA’s FTAC and HMRC, FTI Consulting have devoted a great deal of time interpreting the new legislation for qualifying overseas expenditure and guidance.

Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.